Ritanserin
From Wikipedia, the free encyclopedia
 |
|
|
Ritanserin
|
|
| Systematic (IUPAC) name | |
| 6-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-7-methyl-[1,3]thiazolo[2,3-b]pyrimidin-5-one | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C27H25F2N3OS |
| Mol. mass | 477.569 g/mol |
| SMILES | & |
| Synonyms | Ritanserin |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ritanserin is a neurochemical with wide-reaching possibilities for the treatment of many neurological disorders. When used together with typical antipsychotics in the treatment of schizophrenia is able to decrease negative symptoms and adds some "atypicality" as parkinsonism is slightly decreased.
6-[2-[4-[Bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one
Potent and long-acting 5-HT2 receptor antagonist (Ki = 0.39 nM). Anxiolytic in vivo.
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
